Bristol-Myers Squibb (BMY) vs Regeneron Pharmaceuticals (REGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bristol-Myers Squibb (BMY) has outperformed Regeneron Pharmaceuticals (REGN) over the past year, gaining 33.7% versus a gain of 27.2%. Over five years, REGN leads with a +34.1% price change compared with +2.3% for BMY. Bristol-Myers Squibb is the larger company by market cap ($121.95 billion vs $76.40 billion), about 1.6 times the size, while Regeneron Pharmaceuticals is growing revenue faster (+1.0% vs -0.2%).
On valuation, Bristol-Myers Squibb trades at a lower forward P/E (9.1x vs 12.1x for Regeneron Pharmaceuticals). Bristol-Myers Squibb offers the higher dividend yield (4.20% vs 0.49%). Regeneron Pharmaceuticals converts more of its revenue into profit, with a net margin of 31.4% versus 14.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMY | REGN |
|---|---|---|
| Share price | $59.70 | $742.12 |
| Market cap | $121.95B | $76.40B |
| 1-day change | +0.18% | +0.46% |
| YTD return | +10.68% | -3.85% |
| 1-year return | +33.68% | +27.24% |
| 5-year return | +2.30% | +34.14% |
| P/E ratio (TTM) | 13.12 | 18.27 |
| Forward P/E | 9.06 | 12.07 |
| EPS (TTM) | $4.55 | $40.63 |
| Dividend yield | 4.20% | 0.49% |
| Annual dividend | $2.51 | $3.64 |
| Revenue (latest FY) | $48.19B | $14.34B |
| Revenue growth (YoY) | -0.22% | +0.99% |
| Net income (latest FY) | $7.05B | $4.50B |
| Gross margin | 71.08% | — |
| Operating margin | — | 24.95% |
| Net margin | 14.64% | 31.41% |
| 52-week high | $68.64 | $859.34 |
| 52-week low | $42.52 | $541.00 |
| Distance from 52-week high | -13.02% | -13.64% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +10.84% | +15.38% |
| Average volume | 11.22M | 741.47K |
| Shares outstanding | 2.04B | 101.14M |
| Employees | 32,500 | 15,410 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Regeneron Pharmaceuticals trades at a higher earnings multiple (18.3x vs 13.1x trailing P/E).
- Bristol-Myers Squibb offers a meaningfully higher dividend yield (4.20% vs 0.49%).
- Regeneron Pharmaceuticals is more profitable, keeping 31.4 cents of every revenue dollar as net income versus 14.6 cents for Bristol-Myers Squibb.
About Bristol-Myers Squibb
BMY stock →Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
BMY vs REGN FAQ
Which is bigger, Bristol-Myers Squibb or Regeneron Pharmaceuticals?
Bristol-Myers Squibb (BMY) is larger, with a market capitalization of $121.95B compared with $76.40B for Regeneron Pharmaceuticals (REGN).
Which stock has performed better over the past year, BMY or REGN?
BMY returned +33.68% over the past 12 months, compared with +27.24% for REGN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMY or REGN?
BMY has the lower trailing P/E at 13.1, versus 18.3 for REGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bristol-Myers Squibb or Regeneron Pharmaceuticals?
Bristol-Myers Squibb has the higher yield at 4.20%, compared with 0.49% for Regeneron Pharmaceuticals.
Are Bristol-Myers Squibb and Regeneron Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.